(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 29.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.49%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Alnylam Pharmaceuticals's revenue in 2025 is $3,210,070,000.On average, 33 Wall Street analysts forecast ALNY's revenue for 2025 to be $503,749,988,034, with the lowest ALNY revenue forecast at $429,105,680,864, and the highest ALNY revenue forecast at $586,321,124,284. On average, 32 Wall Street analysts forecast ALNY's revenue for 2026 to be $718,699,169,920, with the lowest ALNY revenue forecast at $611,554,863,522, and the highest ALNY revenue forecast at $848,434,939,196.
In 2027, ALNY is forecast to generate $919,380,059,462 in revenue, with the lowest revenue forecast at $755,162,583,688 and the highest revenue forecast at $1,106,585,339,568.